Last reviewed · How we verify
SHPL-49 Injection
SHPL-49 Injection is a monoclonal antibody targeting PD-1.
SHPL-49 Injection is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | SHPL-49 Injection |
|---|---|
| Sponsor | Shanghai Hutchison Pharmaceuticals Limited |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells, and thereby enhancing the immune response against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
- Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke (PHASE3)
- Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |